과제정보
연구 과제 주관 기관 : Seoul National University Hospital
참고문헌
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. https://doi.org/10.3322/caac.21332
- Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913-2921. https://doi.org/10.1158/0008-5472.CAN-14-0155
- Manji GA, Olive KP, Saenger YM, Oberstein P. Current and emerging therapies in metastatic pancreatic cancer. Clin Cancer Res 2017;23:1670-1678. https://doi.org/10.1158/1078-0432.CCR-16-2319
- Abou-Khalil J, Rocha FG. Surgical strategies and novel therapies for locally advanced pancreatic cancer. J Surg Oncol 2017;116:16-24. https://doi.org/10.1002/jso.24654
- Vogel A, Rommler-Zehrer J, Li JS, McGovern D, Romano A, Stahl M. Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). BMC Cancer 2016;16:817. https://doi.org/10.1186/s12885-016-2798-8
- Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-1703. https://doi.org/10.1056/NEJMoa1304369
- Ottaiano A, Capozzi M, De Divitiis C, et al. Nab-paclitaxel and gemcitabine in advanced pancreatic cancer: the one-year experience of the National Cancer Institute of Naples. Anticancer Res 2017;37:1975-1978. https://doi.org/10.21873/anticanres.11539
- Carrato A, Garcia P, Lopez R, et al. Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study. Expert Rev Pharmacoecon Outcomes Res 2015;15:579-589. https://doi.org/10.1586/14737167.2015.1047349
- Bertocchi P, Abeni C, Meriggi F, et al. Gemcitabine plus nabpaclitaxel as second-line and beyond treatment for metastatic pancreatic cancer: a single institution retrospective analysis. Rev Recent Clin Trials 2015;10:142-145. https://doi.org/10.2174/1574887110666150417115303
- Zhang Y, Hochster H, Stein S, Lacy J. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity. Exp Hematol Oncol 2015;4:29. https://doi.org/10.1186/s40164-015-0025-y
- Cho IR, Kang H, Jo JH, et al. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: a singlecenter cohort study. Semin Oncol 2017;44:420-427. https://doi.org/10.1053/j.seminoncol.2018.01.001
- Lee JJ, Swain SM. Peripheral neuropathy induced by microtubulestabilizing agents. J Clin Oncol 2006;24:1633-1642. https://doi.org/10.1200/JCO.2005.04.0543
- Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010;9:790-803. https://doi.org/10.1038/nrd3253
- Goldstein D, Von Hoff DD, Moore M, et al. Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: a subset analysis from a randomised phase III trial (MPACT). Eur J Cancer 2016;52:85-91. https://doi.org/10.1016/j.ejca.2015.10.017
- Tabernero J, Chiorean EG, Infante JR, et al. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nabpaclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist 2015;20:143-150. https://doi.org/10.1634/theoncologist.2014-0394
- Kunzmann V, Ramanathan RK, Goldstein D, et al. Tumor reduction in primary and metastatic pancreatic cancer lesions with nabpaclitaxel and gemcitabine: an exploratory analysis from a phase 3 study. Pancreas 2017;46:203-208. https://doi.org/10.1097/MPA.0000000000000742
- Luo G, Guo M, Liu Z, et al. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol 2015;22:670-676. https://doi.org/10.1245/s10434-014-4021-y
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247. https://doi.org/10.1016/j.ejca.2008.10.026
- Jones M, Fowler R. Immortal time bias in observational studies of time-to-event outcomes. J Crit Care 2016;36:195-199. https://doi.org/10.1016/j.jcrc.2016.07.017
- Goldstein D, El-Maraghi RH, Hammel P, et al. nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 2015;107:dju413. https://doi.org/10.1093/jnci/dju413
- Lo Re G, Santeufemia DA, Foltran L, Bidoli E, Basso SM, Lumachi F. Prognostic factors of survival in patients treated with nabpaclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience. Oncotarget 2015;6:8255-8260.
- Ueno H, Ikeda M, Ueno M, et al. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 2016;77:595-603. https://doi.org/10.1007/s00280-016-2972-3
- Vogel A, Kullmann F, Kunzmann V, et al. Patients with advanced pancreatic cancer and hyperbilirubinaemia: review and German expert opinion on treatment with nab-paclitaxel plus gemcitabine. Oncol Res Treat 2015;38:596-603. https://doi.org/10.1159/000441310
- Peng L, Bu Z, Ye X, Zhou Y, Zhao Q. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis. Eur J Cancer Care (Engl) 2017;26:e12407. https://doi.org/10.1111/ecc.12407
- Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 2015;75:659-670. https://doi.org/10.1007/s00280-014-2607-5
- Ahn DH, Krishna K, Blazer M, et al. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis. Ther Adv Med Oncol 2017;9:75-82. https://doi.org/10.1177/1758834016676011
- Scheithauer W, Ramanathan RK, Moore M, et al. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol 2016;7:469-478. https://doi.org/10.21037/jgo.2016.01.03
- Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003;6:283-287. https://doi.org/10.1023/B:AGEN.0000029415.62384.ba
- Matsuo Y, Takeyama H, Guha S. Cytokine network: new targeted therapy for pancreatic cancer. Curr Pharm Des 2012;18:2416-2419. https://doi.org/10.2174/13816128112092416
- Yoshie O. Chemokine receptors as therapeutic targets. Nihon Rinsho Meneki Gakkai Kaishi 2013;36:189-196. https://doi.org/10.2177/jsci.36.189
피인용 문헌
- Clinical failure of nanoparticles in cancer: mimicking nature's solutions vol.15, pp.23, 2018, https://doi.org/10.2217/nnm-2020-0234
- Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas vol.10, pp.9, 2018, https://doi.org/10.3390/jcm10091846
- Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients vol.21, pp.1, 2018, https://doi.org/10.1186/s12885-021-09069-9